1. United States Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc.

OOTC:KRBPQ
0.00
USD
+0.00
(+9,900.00%)
-18.27EPS
Nov 16Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-32.4
-28.83
-127.84
-67.24
-63.79
-19.09
-18.41
-18.27
Free Cash Flow per Basic Share
-19.45
-24.87
-50.5
-58.38
-52.58
-19.53
-13.57
-13.46
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-35.08
-35.08
46.48
52.92
-8.91
-7.25
-8.21
-8.21
Tangible Book Value per Share
-35.08
-35.08
46.48
52.92
-8.91
-7.25
-8.21
-8.21
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
2
2
2
2
Net Income, GAAP
-4
-4
-19
-26
-35
-21
-27
-27
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
1
9
24
-12
-16
-18
-18
LT Debt
- -
- -
- -
- -
4
1
- -
- -
Total Equity
- -
2
11
27
-6
-9
-13
-13
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-132.3
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
13
14
14
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
6
4
3
Cash, Cash Equivalents & STI
4
3
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
17
19
21
Payables & Accruals
3
4
5
ST Debt
13
14
14
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
117.88%
38%
Free Cash Flow
- -
64.99%
-7.5%
Net Income, GAAP
- -
94.55%
28.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-14.22
-16.09
-22.46
-327.02
-63.79
2023
-6.07
-6.42
-3.52
-3.73
-19.09
2024
-4.71
-4.53
-4.81
-4.23
-18.41

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pietro Bersani
Full Time Employees
44
Sector
Health technology
Industry
Biotechnology
Address
7707 Fannin Houston TX United States 77054
IPO Date
Oct 16, 2020
Website
kiromic.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Kiromic BioPharma, Inc. (KRBP) is a clinical-stage biotherapeutics company that develops cell therapies targeting solid tumors using non-engineered and engineered allogeneic Gamma Delta T (GDT) cell technologies and its proprietary DIAMOND AI target discovery platform; core product candidates include Deltacel (KB-GDT-01), in Phase 1 trials for non-small cell lung cancer in combination with low-dose radiation, Procel, and Isocel, each addressing unmet needs in immuno-oncology for solid tumors representing 90% of cancers. The company, founded in 2006 and headquartered in Houston, Texas, focuses on the United States market with investigational new drug applications planned for additional GDT-based trials. In March 2025, Kiromic filed for Chapter 7 bankruptcy protection, leading to an asset purchase agreement in April 2025 with Immunocell Therapeutics Inc., one of its investors, to acquire key assets including ongoing clinical trials such as the recruiting Deltacel Phase 1 study with 48 estimated participants set for completion in 2026; this expedited sale aims to minimize disruption to operations and preclinical programs amid prior pipeline prioritization of off-the-shelf allogeneic therapies announced in 2022.